Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-crystallin A2 is a structural protein predominantly expressed in the vertebrate eye lens, where it helps maintain lens transparency and the refractive index[1][6]. It belongs to the beta crystallin family, specifically the beta acidic subgroup, and is characterized by its highly stable structure, as lens fiber cells lose their nuclei during development and retain crystallins throughout life[1][5][6]. The protein can self-associate to form homodimers and can also interact with other beta-crystallins to form heterodimers[1][6]. Mutations in CRYBA2 are associated with inherited cataracts, implicating its crucial role in lens function[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-crystallin A2 (CRYBA2).